Advances in clinical research of virus vector-based COVID-19 vaccines.
10.3760/cma.j.cn112150-20211101-01008
- Author:
Zhuo Pei LI
1
;
Feng Cai ZHU
2
;
Jingxin LI
3
Author Information
1. School of Public Health, Nanjing Medical University, Nanjing 211166, China.
2. NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China.
3. School of Public Health, Nanjing Medical University, Nanjing 211166, China Department of Vaccine Clinical Evaluation, Jiangsu Center for Disease Control and Prevention, Nanjing 210000, China.
- Publication Type:Journal Article
- MeSH:
COVID-19/prevention & control*;
COVID-19 Vaccines;
Genetic Vectors;
Humans;
Vaccines, Synthetic;
Viral Vaccines
- From:
Chinese Journal of Preventive Medicine
2022;56(8):1127-1135
- CountryChina
- Language:Chinese
-
Abstract:
The COVID-19 outbreak at the end of 2019 has accelerated the development and research for COVID-19 vaccines worldwide. Among the COVID-19 vaccines in clinical trials developed via different platforms, recombinant virus vector-based vaccines have shown excellent immunogenicity and efficacy. However, at the same time, there are serious issues such as vaccine safety and pre-existing antibodies against vectors. This article summarizes the design concept and development history of recombinant virus vector-based vaccines, and focuses on the progress in the clinical studies of vector-based COVID-19 vaccines as well as the challenges, in order to provide reference for the research of recombinant vector-based vaccines.
